These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 21508668)

  • 21. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes.
    Cai Y; Qiu S; Gao X; Gu SZ; Liu ZJ
    Apoptosis; 2012 Aug; 17(8):777-83. PubMed ID: 22538442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity.
    D'Orazi G; Garufi A; Cirone M
    IUBMB Life; 2020 Aug; 72(8):1634-1639. PubMed ID: 32593231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
    Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C
    Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
    Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
    Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73.
    Bensaad K; Le Bras M; Unsal K; Strano S; Blandino G; Tominaga O; Rouillard D; Soussi T
    J Biol Chem; 2003 Mar; 278(12):10546-55. PubMed ID: 12519788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs.
    Di Agostino S; Cortese G; Monti O; Dell'Orso S; Sacchi A; Eisenstein M; Citro G; Strano S; Blandino G
    Cell Cycle; 2008 Nov; 7(21):3440-7. PubMed ID: 18948736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
    Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
    Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein.
    Takimoto R; Wang W; Dicker DT; Rastinejad F; Lyssikatos J; el-Deiry WS
    Cancer Biol Ther; 2002; 1(1):47-55. PubMed ID: 12174820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutant and wild-type p53 form complexes with p73 upon phosphorylation by the kinase JNK.
    Wolf ER; McAtarsney CP; Bredhold KE; Kline AM; Mayo LD
    Sci Signal; 2018 Apr; 11(524):. PubMed ID: 29615516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p73-dependent induction of 14-3-3sigma increases the chemo-sensitivity of drug-resistant human breast cancers.
    Sang M; Li Y; Ozaki T; Ono S; Ando K; Yamamoto H; Koda T; Geng C; Nakagawara A
    Biochem Biophys Res Commun; 2006 Aug; 347(1):327-33. PubMed ID: 16814250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.
    Zhang L; Nie L; Maki CG
    Mol Cancer; 2006 Dec; 5():68. PubMed ID: 17150106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.
    Xiao G; Annor GK; Fung K; Keinänen O; Zeglis BM; Bargonetti J
    Mol Pharm; 2021 Jan; 18(1):338-346. PubMed ID: 33289569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73.
    Demma MJ; Wong S; Maxwell E; Dasmahapatra B
    J Biol Chem; 2004 Oct; 279(44):45887-96. PubMed ID: 15308639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p73 beta-expressing recombinant adenovirus: a potential anticancer agent.
    Das S; Nama S; Antony S; Somasundaram K
    Cancer Gene Ther; 2005 Apr; 12(4):417-26. PubMed ID: 15678153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p73 can suppress the proliferation of cells that express mutant p53.
    Willis AC; Pipes T; Zhu J; Chen X
    Oncogene; 2003 Aug; 22(35):5481-95. PubMed ID: 12934108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line.
    Goldschneider D; Blanc E; Raguénez G; Barrois M; Legrand A; Le Roux G; Haddada H; Bénard J; Douc-Rasy S
    J Cell Sci; 2004 Jan; 117(Pt 2):293-301. PubMed ID: 14676279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma.
    Nieto-Rementería N; Pérez-Yarza G; Boyano MD; Apraiz A; Izu R; Díaz-Pérez JL; Asumendi A
    Br J Dermatol; 2009 Mar; 160(3):519-26. PubMed ID: 19067706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?
    Zawacka-Pankau J; Kostecka A; Sznarkowska A; Hedström E; Kawiak A
    Cell Cycle; 2010 Feb; 9(4):720-8. PubMed ID: 20160513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.